Cargando…

Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events

INTRODUCTION: Anticoagulant is the cornerstone of the management of VTE at the cost of a non-negligible risk of bleeding. Reliable and validated clinical tools to predict thromboembolic and hemorrhagic events are crucial for individualized decision-making for the type and duration of anticoagulant t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poénou, Géraldine, Tolédano, Emmanuel, Helfer, Hélène, Plaisance, Ludovic, Happe, Florent, Versini, Edouard, Diab, Nevine, Djennaoui, Sadji, Mahé, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475592/ https://www.ncbi.nlm.nih.gov/pubmed/37671139 http://dx.doi.org/10.3389/fcvm.2023.1132156

Ejemplares similares

In Search of the Appropriate Anticoagulant-Associated Bleeding Risk Assessment Model for Cancer-Associated Thrombosis Patients
por: Poénou, Géraldine, et al.
Publicado: (2022)

Diagnostic Approach for Venous Thromboembolism in Cancer Patients
por: Helfer, Hélène, et al.
Publicado: (2023)

Patient Characteristics and Preferences Regarding Anticoagulant Treatment in Venous Thromboembolic Disease
por: Lanéelle, Damien, et al.
Publicado: (2021)

Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study
por: Plaisance, Ludovic, et al.
Publicado: (2021)

Outside any therapeutic trial prescription of hydroxychloroquine for hospitalized patients with covid-19 during the first wave of the pandemic: A national inquiry of prescription patterns among French hospitalists
por: Bosquet, Antoine, et al.
Publicado: (2022)

Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension
por: Zhu, Yong-Jian, et al.
Publicado: (2021)

Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives
por: Poenou, Geraldine, et al.
Publicado: (2022)

Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants
por: Qureshi, Waqas, et al.
Publicado: (2016)

Factor XI, a potential target for anticoagulation therapy for venous thromboembolism
por: Li, Tingting, et al.
Publicado: (2022)

Immunothrombosis and the Role of Platelets in Venous Thromboembolic Diseases
por: Heestermans, Marco, et al.
Publicado: (2022)

Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis
por: Lopes, Luciane Cruz, et al.
Publicado: (2014)

Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register
por: Palareti, Gualtiero, et al.
Publicado: (2020)

Cancer-Associated Thrombosis on Bevacizumab: Risk of Recurrence and Bleeding When Bevacizumab Is Stopped or Continued
por: Mayenga, Marie, et al.
Publicado: (2023)

Inhibition of Factor XI: A New Era in the Treatment of Venous Thromboembolism in Cancer Patients?
por: Poenou, Géraldine, et al.
Publicado: (2023)

FRI111 Venous Thromboembolism In Cushing Syndrome - A Call For Standardized Anticoagulation Regimen In Hypercortisolism
por: Minasyan, Mari, et al.
Publicado: (2023)

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
por: Lecumberri, Ramón, et al.
Publicado: (2021)

Granulosa tumor: two spontaneous pregnancies after combined medico-surgical treatment: case report and review of the literature
por: Kaakoua, Mohamed, et al.
Publicado: (2023)

Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
por: Wallvik, Niklas, et al.
Publicado: (2020)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
por: de Winter, Maria A, et al.
Publicado: (2023)

New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients
por: Gerotziafas, Grigoris T, et al.
Publicado: (2014)

Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding
por: MacLehose, Richard F., et al.
Publicado: (2021)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Editorial: Venous thromboembolism and pregnancy
por: Tardy, Bernard, et al.
Publicado: (2022)

Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices?
por: Mahé, Isabelle, et al.
Publicado: (2015)

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)
por: Rohla, Miklos, et al.
Publicado: (2019)

Net Clinical Benefit of Direct Oral Anticoagulants in Patients With Cancer and Venous Thromboembolism: A Systematic Review and Trade-Off Analysis
por: Yan, Yi-Dan, et al.
Publicado: (2020)

Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis
por: Lee, Mei-Chuan, et al.
Publicado: (2022)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Venous Thromboembolism Risk Score and Pregnancy
por: Raia-Barjat, Tiphaine, et al.
Publicado: (2022)

Editorial: COVID-19 and Venous Thromboembolism
por: Yamashita, Yugo
Publicado: (2021)

Preeclampsia and Venous Thromboembolism: Pathophysiology and Potential Therapy
por: Raia-Barjat, Tiphaine, et al.
Publicado: (2022)

Platelet Count and Bleeding in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism: Lesson from the RIETE Registry
por: Di Micco, Pierpaolo, et al.
Publicado: (2019)

Differential Presentations of Arterial Thromboembolic Events Between Venous Thromboembolism and Atrial Fibrillation Patients
por: Lin, Yu-Sheng, et al.
Publicado: (2021)

Anticoagulation Management in High Bleeding-Risk ECMO in Adults
por: De Paulis, Stefano, et al.
Publicado: (2022)

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism
por: McRae, Simon J, et al.
Publicado: (2005)

Optimal duration of anticoagulation in patients with venous thromboembolism
por: Prandoni, Paolo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_iig016s6h4d2qobbdi4qq3gl3m